Signaling pathways and targeted therapies in Ewing sarcoma
K Jia, L Cao, Y Yu, D Jing, W Wu, BA Van Tine… - Pharmacology & …, 2024 - Elsevier
Ewing sarcoma, the second most prevalent malignant bone tumor with potential occurrence
in soft tissues, exhibits a high level of aggressiveness, primarily afflicting children and …
in soft tissues, exhibits a high level of aggressiveness, primarily afflicting children and …
Assessment of the circulating levels of immune system checkpoint selected biomarkers in patients with lung cancer
B Safizadeh, M Sadeh, AK Robati, T Riahi… - Molecular Biology …, 2024 - Springer
Background Lung cancer is recognized as one of the leading causes of cancer-related
deaths globally, with a significant increase in incidence and intricate pathogenic …
deaths globally, with a significant increase in incidence and intricate pathogenic …
PD‐L1, STAT3, IL6, and EGFR Immunoexpressions in High‐Grade Osteosarcoma
N Rahmadiani, E Norahmawati… - Advances in …, 2024 - Wiley Online Library
Introduction. Immunotherapy has been widely used in the treatment of various malignancies
with satisfactory results. One of the agents for immunotherapy is an inhibitor of programmed …
with satisfactory results. One of the agents for immunotherapy is an inhibitor of programmed …
Immunocompetent murine model of Ewing sarcoma reveals role for TGFβ inhibition to enhance immune infiltrates in Ewing tumors during radiation
JD Daley, E Mukherjee, AC Tufino, N Bailey, S Bhaskar… - bioRxiv, 2024 - biorxiv.org
Ewing sarcoma (ES) is an aggressive cancer diagnosed in adolescents and young adults.
The fusion oncoprotein (EWSR1:: FLI1) that drives Ewing sarcoma is known to downregulate …
The fusion oncoprotein (EWSR1:: FLI1) that drives Ewing sarcoma is known to downregulate …